tiprankstipranks
Advertisement
Advertisement

DSKYF Stock Latest News

Daiichi Sankyo Terminates Early Cancer Trial DS-9606a: What Investors Should Know
Company AnnouncementsDaiichi Sankyo Terminates Early Cancer Trial DS-9606a: What Investors Should Know
19d ago
DSKYF
Daiichi Sankyo Backs Triple Cholesterol Therapy in New Phase 3 Heart Study
PremiumCompany Announcements
Daiichi Sankyo Backs Triple Cholesterol Therapy in New Phase 3 Heart Study
20d ago
DSKYF
Daiichi Sankyo Advances Triple Cholesterol Combo Pill With Completed Bioequivalence Study
PremiumCompany Announcements
Daiichi Sankyo Advances Triple Cholesterol Combo Pill With Completed Bioequivalence Study
1M ago
DSKYF
Bayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial
PremiumCompany Announcements
Bayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial
2M ago
Daiichi Sankyo Reports January Progress on Ongoing Share Buyback Program
PremiumCompany Announcements
Daiichi Sankyo Reports January Progress on Ongoing Share Buyback Program
2M ago
Daiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data
PremiumCompany AnnouncementsDaiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data
2M ago
Daiichi Sankyo Company (DSKYF) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Daiichi Sankyo Company (DSKYF) Q3 Earnings Cheat Sheet
2M ago
TROPION-SWISH: New Phase IV Study Targets Side-Effect Risk in AstraZeneca and Daiichi Sankyo’s Dato-DXd
Premium
Company Announcements
TROPION-SWISH: New Phase IV Study Targets Side-Effect Risk in AstraZeneca and Daiichi Sankyo’s Dato-DXd
3M ago
AZN
Daiichi Sankyo and Merck Advance Novel ADC Combo in Tough-to-Treat Lung Cancer
PremiumCompany Announcements
Daiichi Sankyo and Merck Advance Novel ADC Combo in Tough-to-Treat Lung Cancer
3M ago
DSKYF
Daiichi Sankyo’s Next Lung Cancer Bet: What the New Merck Partnership Study Means for Investors
PremiumCompany Announcements
Daiichi Sankyo’s Next Lung Cancer Bet: What the New Merck Partnership Study Means for Investors
4M ago
DSKYF
Daiichi Sankyo’s ADC Push in Gastroesophageal Cancer: What Substudy 06D Means for Investors
PremiumCompany Announcements
Daiichi Sankyo’s ADC Push in Gastroesophageal Cancer: What Substudy 06D Means for Investors
4M ago
DSKYF
TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca and Daiichi Sankyo
PremiumCompany Announcements
TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca and Daiichi Sankyo
4M ago
AZN
Daiichi Sankyo’s CLEAR Taiwan Study: A New Chapter in Lipid-Lowering Therapy
PremiumCompany AnnouncementsDaiichi Sankyo’s CLEAR Taiwan Study: A New Chapter in Lipid-Lowering Therapy
4M ago
DSKYF
3 Best Japanese Stocks to Invest In, According to AI Analyst
Premium
Market News
3 Best Japanese Stocks to Invest In, According to AI Analyst
4M ago
GS
AZN
Daiichi Sankyo Wins Patent Dispute Appeal Against Seagen
Premium
Company Announcements
Daiichi Sankyo Wins Patent Dispute Appeal Against Seagen
4M ago
DSKYF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
DSKYF Upcoming Earnings Report: What to Expect?
5M ago
Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment
PremiumCompany Announcements
Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment
5M ago
DSKYF
Daiichi Sankyo’s Promising Pediatric Cancer Study: A Potential Game-Changer
PremiumCompany Announcements
Daiichi Sankyo’s Promising Pediatric Cancer Study: A Potential Game-Changer
5M ago
DSKYF
Daiichi Sankyo’s Promising Gastrointestinal Cancer Study: A Market Game-Changer?
PremiumCompany Announcements
Daiichi Sankyo’s Promising Gastrointestinal Cancer Study: A Market Game-Changer?
5M ago
DSKYF
Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Gastrointestinal Cancer Treatment
PremiumCompany AnnouncementsDaiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Gastrointestinal Cancer Treatment
5M ago
DSKYF
Daiichi Sankyo’s Promising Breast Cancer Study: A Financial Perspective
Premium
Company Announcements
Daiichi Sankyo’s Promising Breast Cancer Study: A Financial Perspective
5M ago
DSKYF
Daiichi Sankyo’s Promising Phase 2 Breast Cancer Study: A Potential Game-Changer
Premium
Company Announcements
Daiichi Sankyo’s Promising Phase 2 Breast Cancer Study: A Potential Game-Changer
5M ago
DSKYF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >